New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
10:34 EDTTKPYY, APRIApricus Biosciences reports Takeda accepts first shipment of Vitaros
Apricus Biosciences (APRI) announced earlier that Takeda Pharmaceuticals (TKPYY), the company's partner in the United Kingdom, has accepted the first shipment of Vitaros, Apricus' topical treatment for erectile dysfunction. Apricus CEO Richard Pascoe said, "With the commercial availability of Vitaros in the United Kingdom, Takeda is in a position to finalize its pre-launch activities in an effort to be the first Vitaros commercial partner to offer an on demand topical cream treatment for men with erectile dysfunction." Shares of Apricus are up about 16% to $2.34 in morning trading.
News For APRI;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
07:16 EDTAPRIApricus Biosciences, Ferring Pharmaceuticals sign distribution agreement
Subscribe for More Information
September 21, 2015
16:28 EDTTKPYYIntra-Cellular announces completion of Phase 1 studies for ITI-214
Intra-Cellular Therapies (ITCI) announced that it is assuming sponsorship of the Investigational New Drug Application for studies related to ITI-214. ITI-214 is a novel, potent phosphodiesterase type 1 inhibitor. Multiple human clinical Phase 1 studies have been completed. In these studies, ITI-214 demonstrated a favorable safety profile and was generally well-tolerated across a broad range of doses both in healthy volunteers and in patients with schizophrenia with a pharmacokinetic profile that supports once daily dosing. Under a license agreement, Takeda (TKPYY) conducted four Phase 1 studies. A single rising dose study was conducted in the US in healthy male and female, Japanese and non-Japanese volunteers. In a second US study ITI-214 was administered once daily over 14 days to healthy volunteers and patients with stable schizophrenia. In a third study, conducted in Japan, ITI-214 was administered for 7 days at multiple rising oral doses in both male and female healthy volunteers. A fourth study compared the relative bioavailability of oral formulations of ITI-214 used in all previous studies to an immediate-release tablet, either with or without food in healthy volunteers. The Company is currently evaluating ITI-214 for several indications including cognition in patients with Parkinson's disease, dementia, schizophrenia and other CNS and non-CNS disorders.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use